CN102056605A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN102056605A
CN102056605A CN2008801296335A CN200880129633A CN102056605A CN 102056605 A CN102056605 A CN 102056605A CN 2008801296335 A CN2008801296335 A CN 2008801296335A CN 200880129633 A CN200880129633 A CN 200880129633A CN 102056605 A CN102056605 A CN 102056605A
Authority
CN
China
Prior art keywords
regulator
disease
cell
group
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801296335A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·绍尔
罗伯特·罗德里格斯
保罗·宾厄姆
拉克玛尔·W·波特尤
苏珊娜·扎卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102056605A publication Critical patent/CN102056605A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801296335A 2008-04-04 2008-04-04 药物组合物 Pending CN102056605A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/004410 WO2009123597A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CN102056605A true CN102056605A (zh) 2011-05-11

Family

ID=41135840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801296335A Pending CN102056605A (zh) 2008-04-04 2008-04-04 药物组合物

Country Status (10)

Country Link
EP (1) EP2268278A4 (pt)
JP (1) JP2011516473A (pt)
KR (1) KR20110025168A (pt)
CN (1) CN102056605A (pt)
AU (1) AU2008354009A1 (pt)
BR (1) BRPI0821894A2 (pt)
CA (1) CA2720396A1 (pt)
IL (1) IL208387A0 (pt)
MX (1) MX2010010867A (pt)
WO (1) WO2009123597A1 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142643A (zh) * 2012-12-19 2015-12-09 基石医药公司 药物化合物
CN110590624A (zh) * 2019-09-26 2019-12-20 苏州富士莱医药股份有限公司 一种硫辛酸衍生物8-（乙基二硫烷基）-6-（苯基二硫烷基）辛酸的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343847B (es) 2010-07-08 2016-11-24 Wrigley W M Jun Co Goma de mascar que contiene una base de goma de matriz de gelatina reticulada.
US9421234B2 (en) * 2011-05-20 2016-08-23 Nutramax Laboratories, Inc. Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
CA2863600A1 (en) * 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
AU2014398232B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
WO2015195071A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
WO2023012305A1 (en) * 2021-08-04 2023-02-09 Cytacoat Ab Disulfide compounds as medicaments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2789991A (en) * 1954-05-20 1957-04-23 American Cyanamid Co Substituted disulfones
JPS61198148A (ja) * 1985-01-29 1986-09-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
DK1624060T3 (da) * 1998-03-20 2012-04-10 Commw Scient Ind Res Org Kontrol af genekspression
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6331559B1 (en) * 1998-10-26 2001-12-18 The Research Foundation Of State University Of New York At Stony Brook Lipoic acid derivatives and their use in treatment of disease
DE19904794A1 (de) * 1999-02-05 2000-08-10 Biotechnolog Forschung Gmbh Verfahren zur Verbesserung des Primärstoffwechsels von Säugerzelllinien
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
US7108977B2 (en) * 2000-05-19 2006-09-19 Hoffmann-La Roche Inc. Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
JP5412423B2 (ja) * 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
AU2008242827B2 (en) * 2007-04-18 2014-06-05 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142643A (zh) * 2012-12-19 2015-12-09 基石医药公司 药物化合物
CN105142643B (zh) * 2012-12-19 2021-09-03 基石医药公司 药物化合物
CN110590624A (zh) * 2019-09-26 2019-12-20 苏州富士莱医药股份有限公司 一种硫辛酸衍生物8-（乙基二硫烷基）-6-（苯基二硫烷基）辛酸的制备方法
CN110590624B (zh) * 2019-09-26 2021-02-26 苏州富士莱医药股份有限公司 一种硫辛酸衍生物8-(乙基二硫基)-6-(苯基二硫基)辛酸的制备方法

Also Published As

Publication number Publication date
EP2268278A4 (en) 2011-11-09
BRPI0821894A2 (pt) 2015-07-21
AU2008354009A1 (en) 2009-10-08
WO2009123597A1 (en) 2009-10-08
EP2268278A1 (en) 2011-01-05
JP2011516473A (ja) 2011-05-26
MX2010010867A (es) 2011-05-25
CA2720396A1 (en) 2009-10-08
IL208387A0 (en) 2010-12-30
KR20110025168A (ko) 2011-03-09

Similar Documents

Publication Publication Date Title
CN102056605A (zh) 药物组合物
Cameron et al. Metformin selectively targets redox control of complex I energy transduction
Gan et al. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity
ES2663789T3 (es) Compuesto de pirazol-amida y usos medicinales del mismo
JP2017078056A (ja) 有機セレン化合物の組成物およびその使用方法
Sheng et al. Identification of pyruvate carboxylase as the cellular target of natural bibenzyls with potent anticancer activity against hepatocellular carcinoma via metabolic reprogramming
US10450337B2 (en) Pharmaceutical compounds
US20200331931A1 (en) Pharmaceutical compounds
CN102089276A (zh) 酶结构、活性和/或表达水平的调节
Eberhardt et al. EFHD1 ablation inhibits cardiac mitoflash activation and protects cardiomyocytes from ischemia
US10526357B2 (en) Pharmaceutical compounds
US20050004225A1 (en) Oxidoreductase inhibitors and methods of screening and using thereof
Steenberge et al. Coenzyme Q4 is a functional substitute for coenzyme Q10 and can be targeted to the mitochondria
US20230201168A1 (en) New therapy for the treatment of tumors
Bushau-Sprinkle Mechanistic insight of the role of NHERF1 in cisplatin-induced acute kidney injury.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110511